Jinwu Financial News | Deqi Pharmaceutical-B (06996) announced that the Macao Drug Administration has approved a new drug application (NDA) for Sivio (selinisol) combined with dexamethasone (Xd) for the treatment of adult patients with recurrent and/or refractory multiple myeloma (RRMM) who have received at least four previous treatments and are refractory to treatment with at least two proteasome inhibitors (PIs), two immunomodulators (IMIDs) and one anti-CD38 monoclonal antibody drug.
Sivio is the world's first approved selective oral XPO1 inhibitor for nuclear export protein. It has a novel mechanism of action, has a synergistic effect in combination therapy, works quickly, and has a long-lasting response.